Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/RJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed both in biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. A growing number of new agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon, requiring a precision approach. Watch PeerView’s latest educational video, based on a recent live symposium, and learn to better navigate biomarker-driven, individualized therapy for patients with EGFR-mutated NSCLC. Experts analyze the expanding evidence base and provide actionable, case-based guidance for improving testing, interpretation of results, and therapeutic decision-making for